PCN100 COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN

Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71995-7
https://www.valueinhealthjournal.com/article/S1098-3015(11)71995-7/fulltext
Title : PCN100 COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71995-7&doi=10.1016/S1098-3015(11)71995-7
First page : A270
Section Title : RESEARCH POSTER ABSTRACTS
Open access? : No
Section Order : 154
Categories :
Tags :
Regions :
ViH Article Tags :